Biotechnology

Nationwide Children's Hospital is constructing a $100 million gene therapy manufacturing center in Columbus, Ohio. The 185,000-sf facility will enable Andelyn Biosciences, a for-profit subsidiary of Nationwide Children's, to supply pharmaceutical and biotechnology companies with genetic material for use in research and clinical trials. Located in The Ohio State University's Innovation District, the leased structure will feature advanced cGMP environments for commercial-scale manufacturing.

The life sciences industry has become the great hope in real estate, as we face the most significant public health crisis in a century. While other industries have slowed and suffered as a result of sheltering in place and working from home, science facilities have remained operational and even have thrived in prime markets, as the industry continues to search for medical breakthroughs. The downturn in other industries has left buildings vacant. The life science market, on the other hand, continues to experience some of the lowest vacancy and highest employment rates. For life science organizations in the prime U.S. markets, there simply remains a shortage of available research-capable space. Enter the big pivot to science.

The University of Oregon dedicated the first phase of the Phil and Penny Knight Campus for Accelerating Scientific Impact in December of 2020 in Eugene. Designed by Ennead Architects and Bora Architects to encourage interaction and collaboration, the $225 million, 160,000-sf building offers leading-edge biomedical laboratories, core facilities, classrooms, and an innovation center.

Alexandria Real Estate Equities has attained the world's first WELL Health-Safety Rating for laboratory space at Alexandria LaunchLabs in New York City. Augmenting the center’s existing WELL certification for building design, the WELL Health-Safety Rating for Facilities Operations and Management includes further measures to protect the health of tenants, employees, visitors, and service personnel. Protocols at Alexandria LaunchLabs include:

The Centre for Process Innovation (CPI) began construction in October of 2020 on the Medicines Manufacturing Innovation Centre in Inchinnan in the United Kingdom. Created in collaboration with the University of Strathclyde, GSK, and AstraZeneca, the £42 million facility will enable the development of new pharmaceutical production methods that will be proven at scale in a GMP environment.

Lincoln Property Company is creating a mixed-use campus in Lexington, Mass. Designed by DiMella Shaffer, the development will include a laboratory building providing 95,000 sf of Class A research space linked by a central promenade to a 125,000-sf office facility. Strategically sited in the burgeoning life sciences district along the Route 128 corridor, the complex will include a community hub with a café to encourage interaction and collaboration between tenants, as well as a 502-space parking garage.

Merck is constructing a $69 million facility for the production of high-potency active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) compounds. Representing an expansion of the company's existing campus near Madison, the 70,000-sf structure will feature containment environments specifically designed for the manufacture of substances with single-digit nanogram occupational exposure limits. The building will allow the large-scale production of increasingly potent compounds for the creation of innovative cancer therapeutics.

Facility Logix, EwingCole, and Biggins Lacy Shapiro have launched Rapid Reshore & Development (RR&D) to provide turnkey professional services to the life sciences and biopharmaceutical industries. Addressing many of the logistical challenges faced by companies developing drugs, vaccines, and medical devices, the alliance represents an evolution from transaction-driven service models to a holistic focus on client needs.

Construction began in October of 2020 on the $44.2 million Discovery Square 2 building in Rochester, Minn. Designed by RSP Architects, the 125,000-sf facility will offer leasable research environments for life science companies. Sited in the Destination Medical Center district, the five-story structure will feature advanced laboratory infrastructure, centralized common spaces, and a physical connection to the adjacent One Discovery Square building.

King Street Properties has fully leased a 214,440-sf research facility in Lexington, Mass., to four pharmaceutical companies. Designed by R E Dinneen Architects & Planners, the four-story building will offer leading-edge lab and office environments for biomedical research. JLL is the leasing agent for the development, which has yet to open. Tenants include:

Fujifilm Diosynth Biotechnologies broke ground in August of 2020 on the $55 million Advanced Therapies Innovation Center in College Station, Texas. Representing an expansion of Fujifilm's cGMP manufacturing campus, the 60,000-sf facility will feature dedicated labs for process development and innovation. Research environments with BSL-2 capabilities will integrate advanced technologies for upstream, downstream, and analytical development.

Codiak BioSciences is constructing a 12,000-sf clinical manufacturing center in Lexington, Mass. The project includes the build-out of a leased lab and office building to create a GMP facility for the production of exosome therapeutics. Codiak is incorporating G-CON Manufacturing's PODs into the center to provide flexible cleanroom capacity. The prefabricated units offer exceptional scalability and mobility, and can be easily repurposed to meet future needs.

CRISPR Therapeutics signed a full-building lease in July of 2020 for a 263,500-sf facility in Boston's Seaport district. Breakthrough Properties is the developer for the project, which was designed by Payette to provide best-in-class laboratory environments for life science research. Both LEED Gold and Fitwel certification will be sought for the structure, which will offer multiple amenities including outdoor terraces and a fitness center.

Lincoln Property Company broke ground in July of 2020 on a 140,000-sf life science building in Waltham, Mass. Designed by DiMella Shaffer in collaboration with AHA Consulting Engineers, the four-story structure will offer 35,000 sf of flexible and customizable office and laboratory space on each floor. A robust mechanical penthouse will support the installation of sophisticated infrastructure, and highly resilient energy and telecommunications services will be ensured by an onsite emergency power supply.

The Cell and Gene Therapy Catapult is planning to create the Manufacturing Innovation Centre in Braintree in the United Kingdom. Supported by £100 million in government funding, the project will enable mass production of a COVID-19 vaccine. An existing pharmaceutical plant has been purchased from Benchmark Holdings at a cost of £16 million. The structure's GMP infrastructure for antigen production, formulation, process development, and scale manufacturing will be repurposed and enhanced. Completion is expected in December of 2021.